Copyright
©The Author(s) 2023.
World J Hepatol. Jan 27, 2023; 15(1): 89-106
Published online Jan 27, 2023. doi: 10.4254/wjh.v15.i1.89
Published online Jan 27, 2023. doi: 10.4254/wjh.v15.i1.89
Aetiology | n | % of total cohort | Mean/median age (yr) | % male |
Tier 1 | ||||
ArLD | 16143 | 26.1% | 54.9/55 | 67.8% |
NAFLD | 13390 | 21.6% | 57/58 | 47% |
Metabolic | 7131 | 11.5% | 63/67 | 52.5% |
HCV | 2889 | 4.7% | 43/41 | 66.8% |
ArLD overlap | 2979 | 4.8% | 51.2/51 | 65.3% |
Autoimmune liver diseases | 2312 | 3.7% | 61.8/64 | 20.5% |
HBV | 904 | 1.5% | 43.5/39 | 53.3% |
Non ArLD overlap | 955 | 1.5% | 51.2/51 | 55.8% |
Tier 2 | ||||
Hepatitis not specified | 6069 | 9.8% | 63/66 | 50.9% |
Congestive hepatopathy | 894 | 1.4% | 64.7/70 | 49.6% |
Toxic liver disease | 820 | 1.3% | 46.3/44 | 38.4% |
Tier 3 | ||||
Miscellaneous | 7430 | 12% | 66.7/70 | 42% |
- Citation: Pembroke TPI, John G, Puyk B, Howkins K, Clarke R, Yousuf F, Czajkowski M, Godkin A, Salmon J, Yeoman A. Rising incidence, progression and changing patterns of liver disease in Wales 1999-2019. World J Hepatol 2023; 15(1): 89-106
- URL: https://www.wjgnet.com/1948-5182/full/v15/i1/89.htm
- DOI: https://dx.doi.org/10.4254/wjh.v15.i1.89